This is an open-label trial in which 100 patients with rituximab-refractory indolent B-cell NHL were treated bendamustine 120 mg/m 2 on days 1 and 2 of every 21-day cycle for six to eight cycles.

The PFS benefit with pirtobrutinib was consistent against both idelalisib-rituximab and bendamustine-rituximab and among clinical subgroups, including age, sex, ECOG status, number of prior ...

Treatment in the frontline setting has become well defined, with a combination of immunotherapy and chemotherapy -- rituximab and bendamustine -- the "go-to" treatment in the U.S. for indolent ...

He achieved a complete remission with 6 cycles of bendamustine and rituximab (BR), and has been monitored clinically since then. He has a history of hypertension, for which he takes lisinopril 10 ...

EMA committee recommends approval of AstraZeneca’s fixed-duration Calquence-based regimens for 1st-line chronic lymphocytic leukaemia: Cambridge, UK Wednesday, April 30, 2025, 1 ...

CD20 is found on the surface of all normal B cells and on 95% of cancerous B cells. Rituximab, developed in partnership by Roche and Biogen Idec, was the first anti-CD20 monoclonal antibody to be ...

That approval also included first-line use of the drug for eligible patients unsuitable for chemo-immunotherapy, typically carried out with bendamustine plus rituximab, or dexamethasone plus ...

compared with standard bendamustine and Rituxan therapy. Results of MURANO published last week will form the basis of a regulatory filing in patients with relapsed or refractory CLL – but Peter ...

AstraZeneca has announced that a fixed-duration regimen of Calquence (acalabrutinib) in combination with venetoclax, with or ...

This is an open-label trial in which 100 patients with rituximab-refractory indolent B-cell NHL were treated bendamustine 120 mg/m 2 on days 1 and 2 of every 21-day cycle for six to eight cycles.